



Neuren Pharmaceuticals Ltd
Level 2, 57 Wellington Street
Freemans Bay, Auckland, New Zealand
office: +64 9 529 3940
fax: +64 9 361 7981
enquiries@neurenpharma.com
www.neurenpharma.com

30 April 2010

The Company Announcements Office
ASX Limited

BY E-LODGEMENT

Dear Sir/Madam

Please find attached Appendix 4C for Neuren Pharmaceuticals Limited for the first quarter ended 31 March 2010.

The results presented are consistent with the Company's expectations based on previously announced business plans.

As previously announced, Neuren has a convertible loan facility in place and drew down A\$600,000 in the quarter. This facility is available until December 2011 and provides minimum monthly funding which commenced with A\$400,000 in January 2010, followed by ten tranches of A\$100,000, and subsequent tranches of A\$60,000.

Neuren also continues to receive grant funding from the US Army towards the direct costs of the Phase 2 trial of NNZ-2566 which is about to commence. The Company periodically requests and receives in advance funding instalments to meet trial costs expected to arise within the next one or two months, and this process will continue through the course of the Phase 2 trial.

Yours sincerely

A handwritten signature in black ink, appearing to read "Rob Turnbull", is written over a thin horizontal line.

Mr Rob Turnbull
Chief Financial Officer

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Neuren Pharmaceuticals Limited

ARBN

111 496 130

Quarter ended ("current quarter")

31 March 2010

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$NZ'000	Year to date (3 months) \$NZ'000
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) staff costs	(399)	(399)
(b) advertising and marketing	-	-
(c) research and development	(1,059)	(1,059)
(d) leased assets	-	-
(e) other working capital	(445)	(445)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	19	19
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other (provide details if material)		
Grants received	485	485
Net GST refunded	50	50
Patent costs	(318)	(318)
Net operating cash flows	(1,667)	(1,667)

+ See chapter 19 for defined terms.

	Current quarter \$NZ'000	Year to date (3 months) \$NZ'000
1.8 Net operating cash flows (carried forward)	(1,667)	(1,667)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	-	-
1.14 Total operating and investing cash flows	(1,667)	(1,667)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	(5)	(5)
1.19 Dividends paid	-	-
1.20 Other – Convertible notes	753	753
Expenses related to share capital	(333)	(333)
Net financing cash flows	415	415
Net increase (decrease) in cash held	(1,252)	(1,252)
1.21 Cash at beginning of quarter/year to date	4,232	4,232
1.22 Exchange rate adjustments	56	56
1.23 Cash at end of quarter	3,036	3,036

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

	Current quarter \$NZ'000
1.24 Aggregate amount of payments to the parties included in item 1.2	284
1.25 Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

The aggregate amount of payments comprises remuneration paid to the Chief Medical Officer of Neuren Pharmaceuticals Limited for the quarter and the payment of directors fees accrued but unpaid since June 2008.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

During the quarter convertible notes amounting to A\$500,000 were converted to 17,831,998 ordinary shares and 17,831,998 options in the Company.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$	Amount used \$
3.1 Loan facilities: Convertible Loan Facility expiring December 2011	Minimum A\$2,730,000	A\$1,150,000
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$NZ'000	Previous quarter \$NZ'000
4.1 Cash on hand and at bank	314	308
4.2 Deposits at call	2,722	3,924
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	3,036	4,232

4.5 Total cash at the end of the quarter includes NZ\$855,000 received under grant and funding arrangements which require this amount to be spent on future specific research and development programmes.

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration	N/A	N/A
5.3 Consideration for acquisition or disposal	N/A	N/A
5.4 Total net assets	N/A	N/A
5.5 Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



.....
Rob Turnbull
Chief Financial Officer
30 April 2010

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 - itemised disclosure relating to acquisitions
 - 9.4 - itemised disclosure relating to disposals
 - 12.1(a) - policy for classification of cash items
 - 12.3 - disclosure of restrictions on use of cash
 - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.